康艾注射液配合化疗治疗晚期非小细胞肺癌的临床研究

目的:观察康艾注射液联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法:72例晚期NSCLC患者随机分为康艾注射液联合化疗组(36例)和单纯化疗组(36例),观察两组患者化疗2个疗程后客观有效率及临床获益率、化疗期间及化疗后两组患者的不良反应及生存质量的对比情况。结果:康艾注射液联合化疗组有效率及临床获益率均略高于单纯化疗组,差异有统计学意义(P0.05)。康艾注射液联合化疗组化疗不良反应低于单纯化疗组,差异有统计学意义(P0.05)。康艾注射液联合化疗组生存质量优于单纯化疗组,两组比较差异有统计学意义(P0.05)。结论:康艾注射液能提高晚期非小细胞肺癌患者的近期疗效,减轻化疗的不良反应,提高生存质量。

Clinical Observation of Combined Kangai Injection with Chemotherapy in The Treatment of Advanced Non-small Cell Lung Cancer

Objective：To observe the efficacy and adverse reactions of Kangai injection plus chemotherapy in the treatment of advanced non -small cell lung cancer（NSCLC） . Methods：Seventy -two cases with advanced NSCLC were randomly divided into two groups ,36 patients of test group were treated with Kangai injection combined with chemotherapy,36 patients of control group were only treated with chemotherapy. The chemotherapy effect, side effects and improvement of thequality of life of two groups were evaluated during and after chemotherapy. Results：Kangai injection combined with chemotherapy group and the clinical benefit rate was slightly higher than the sin- gle chemotherapy group, the difference was statistically significant （ P 〈 0. 05 ）. Toxicity of Kangai combined chemotherapy group chemo- therapy is lower than the single chemotherapy group, the difference was statistically significant （ P 〈 0. 05 ）. Kangai combined chemother- apy group quality of life is better than simple chemotherapy group, there was significant difference between 2 groups （ P 〈 0. 05 ）. Con- clusion：Kangai injection can improve the curative effect in patients with advanced non small cell lung cancer, reduce the side effects of chemotherapy, improve the quality of life.